biote Corp. (NASDAQ:BTMD) Short Interest Update

biote Corp. (NASDAQ:BTMD) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,477,700 shares, an increase of 22.6% from the December 31st total of 1,205,571 shares. Based on an average daily volume of 206,954 shares, the days-to-cover ratio is currently 7.1 days. Currently, 4.3% of the company’s stock are short sold. Currently, 4.3% of the company’s stock are short sold. Based on an average daily volume of 206,954 shares, the days-to-cover ratio is currently 7.1 days.

Institutional Investors Weigh In On biote

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Strs Ohio grew its stake in shares of biote by 50.9% in the fourth quarter. Strs Ohio now owns 166,300 shares of the company’s stock worth $432,000 after acquiring an additional 56,100 shares during the last quarter. Man Group plc boosted its holdings in biote by 9.9% in the 3rd quarter. Man Group plc now owns 70,383 shares of the company’s stock valued at $211,000 after purchasing an additional 6,356 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in biote in the 3rd quarter worth $61,000. Squarepoint Ops LLC bought a new position in shares of biote during the 3rd quarter worth about $49,000. Finally, Franklin Resources Inc. bought a new position in shares of biote during the 3rd quarter worth about $58,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

biote Stock Down 5.9%

BTMD stock traded down $0.14 during trading hours on Tuesday, hitting $2.14. The company’s stock had a trading volume of 207,336 shares, compared to its average volume of 176,626. The stock has a 50 day moving average price of $2.52 and a two-hundred day moving average price of $2.94. biote has a 12 month low of $2.03 and a 12 month high of $5.37. The company has a market capitalization of $97.48 million, a PE ratio of 2.70 and a beta of 1.15.

biote (NASDAQ:BTMD) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.17. The business had revenue of $47.96 million during the quarter, compared to analyst estimates of $47.76 million. biote had a net margin of 14.72% and a negative return on equity of 21.86%. Sell-side analysts expect that biote will post 0.75 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Wall Street Zen downgraded biote from a “buy” rating to a “hold” rating in a research note on Sunday, November 2nd. Weiss Ratings reissued a “sell (d+)” rating on shares of biote in a research report on Monday, December 29th. B. Riley restated a “neutral” rating on shares of biote in a report on Thursday, November 6th. Finally, Truist Financial set a $5.00 target price on shares of biote in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, biote presently has a consensus rating of “Hold” and a consensus price target of $5.67.

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.